Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAD: Harmonization of Tau PET Tracers
NCT05361382Phase 1Active, not recruiting
- Start
- Mar 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of flortaucipir and florquinitau in Alzheimer's disease (AD). Primary endpoints: Cross-sectional tau PET uptake values at 2 years and Longitudinal change in tau PET uptake values over 18 months at 5 years. Started Mar 2022; status: active, not recruiting.
02
Drugs
flortaucipirflorquinitau
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05361382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05361382.